Skip to content
Bored Studies
RecruitingPhase 3

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Novo Nordisk A/S · NCT07745504

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
285
US sites recruiting
10
Study start
August 4, 2026
Record last updated
September 4, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.

Being studied: Cagrilintide; Placebo cagrilintide; Placebo semaglutide

Conditions: Overweight; Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion criteria

  • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the informed consent.
  • Body mass index (BMI) greater than or equal to (>=) 30.0 kilograms per square meter (kg/m\^2), or BMI >= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Exclusion criteria

  • History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
  • Previous dosing of marketed or non-marketed amylin-based compounds.
  • Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.

Recruiting US locations

Study contacts (from the official record)

  • Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
All weight loss studies in Georgia →
A Research Study to Compare Two Different Versions of Injectable… (NCT07745504) | Bored Studies